23 A combination of these data with a meta-analysis 3 reviewing rosiglitazone use, which showed a 43% increase in the rate of myocardial infarction (p=0.003) and a 64% nonsignificant increased risk of CV death (p=0.006) in patients using the drug, ultimately compelled the FDA to take immediate action toward changing the standard requirements for documenting safety of new medications seeking approval for T2DM treatment
These effects often matter most when they interfere with fluids, nutrition, work, sleep, or diabetes management
Appetite suppression does not equal leptin repair Improved glucose numbers do not equal resolved insulin resistance Weight loss does not equal inflammation reduction Patients can lose significant weight while: Gut motility slows Protein intake drops Micronutrient intake declines Lean mass erodes Resting metabolic rate decreases From a functional medicine lens, this is cosmetic improvement layered over unresolved dysfunction
Supports heart and energy metabolism
Its a starting point, not a diagnosis
The symptoms of gastroparesis may be mild or severe, ranging from bloating, nausea, and reduced appetite to vomiting, abdominal pain, and malnutrition
-1775582746855.png&w=3840&q=75)
